Navigation Links
Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
Date:9/11/2007

hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes,

or hypercoagulable disorders).

* In some female patients, menses have resumed following PROCRIT therapy;

the possibility of pregnancy should be discussed and the need for

contraception evaluated.

* Prior to and regularly during PROCRIT therapy monitor iron status;

transferrin saturation should be greater than or equal to 20% and

ferritin should be greater than or equal to 100 ng/mL. During therapy

absolute or functional iron deficiency may develop and all patients will

eventually require supplemental iron to adequately support

erythropoiesis stimulated by PROCRIT.

* In studies, the most common side effects included fever (pyrexia),

diarrhea, nausea, vomiting, swelling of hands or feet (edema), lack or

loss of strength or weakness (asthenia, fatigue), shortness of breath,

high blood pressure, headache, joint pain (arthralgias), abnormal skin

sensations (as tingling or tickling or itching or burning; paresthesia),

rash, constipation, and upper respiratory infection.

Please visit http://www.procrit.com for the full Prescribing Information, including the Boxed Warning.

About Ortho Biotech Products, L.P.

Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. Since it was founded in 1990, Ortho Biotech and its worldwide affiliates have earned a global reputation for researching, manufacturing and marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplante
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
6. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
7. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
8. Prana Biotechnology Presents New Key Findings on PBT2
9. Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
10. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering and developing innovative therapeutics, primarily ... today announced that it received a Notice of ... Trademark Office (USPTO) on its novel, self-delivering ... Interference in Ocular Indications," covers methods of ...
(Date:6/3/2015)... GAITHERSBURG, Md. , June 3, 2015  GenVec, ... collaboration with Dr. David T. Curiel and ... University at St. Louis (WUSTL).  ... Center and the Cancer Biology Division within the Department ... GenVec and the WUSTL team will create modified versions ...
(Date:6/3/2015)... , June 3, 2015  Armetheon, Inc., ... drugs for cardiovascular diseases, today announced that ... appointed Chief Executive Officer, effective immediately. Dr. Kakkar ... global, high-growth enterprises, with a successful track record ... human health. With expertise that includes the development ...
Breaking Medicine Technology:RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 2RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 3RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 4GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 2GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 3GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 4Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 2Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 3Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 4
... Oct. 26 Accuray,Incorporated (Nasdaq: ARAY ), ... today that the company is partnering with The ... Houston, Texas to launch a prospective,clinical study to ... in the study will be randomly assigned to ...
... announces data presented at AACR-NCI-EORTC ... ... (CTI) (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a,wholly-owned ... candidates during the 19th annual AACR-NCI-EORTC Symposium. "These studies show ...
Cached Medicine Technology:M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients 2M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients 3M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 5
(Date:6/3/2015)... MD (PRWEB) June 03, 2015 On the ... a $13 billion industry by 2020 ( click here ... Markets), computer scientists believe Baltimore has the talent ... industry in which genetic code and other biological data are ... cure disease. “Baltimore contains all the elements of a ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Array ... exchange technology, has announced that CEO Jonathan Rickert will ... 2015 on June 4, 2015. The session will ... technologies are disrupting traditional business models in health care, ... value. , WHAT: Digital Transformation and the Health ...
(Date:6/3/2015)... Justina Molzon, MS Pharm, JD will ... upcoming Annual Meeting. DIA’s Global Inspire Award program recognizes ... excellence, and commitment to service on a global scale. ... Service Award that recognizes the “Member of the Year” ... and who has contributed to the advancement of DIA’s ...
(Date:6/3/2015)... The panel of independent experts has spent weeks considering ... the awards presented tonight at TU-Automotive Detroit 2015. , ... best-of-the-best can now be revealed as: , Car Maker ... rivals aside by taking the coveted Car Maker of ... panel of expert judges., Stand out comments included: ...
(Date:6/3/2015)... 2015 According to an article published ... intercepted fake oxycodone pills which actually contained the potent ... look legitimate, and even sported the “A/215” imprint common ... consuming 30 mg oxycodone to be exceptionally critical of ... buy them illegally on the street. Fentanyl is an ...
Breaking Medicine News(10 mins):Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3
... patients, study finds , MONDAY, March 8 (HealthDay News) ... they catch it early, but a new study suggests ... risk of developing the disease. , If their ophthalmologists ... in the eye won,t need to take prescription anti-glaucoma ...
... if parent had brain attack by 65, chances of same ... -- If your mother or father had a stroke by ... a stroke by that age are increased fourfold, U.S. researchers ... such as high blood pressure, obesity and smoking. These risks ...
... Virologists surprised to ... to be reactivated to an infectious form. , ... TAMPA, FL (PRWEB) February 20, 2010 -- Human herpesvirus 6 ... lasts for the rest of a person’s life. In a study funded by the ...
... , ... ... ... ...
... ... ... ... ...
... ... ... , ... , , ...
Cached Medicine News:Health News:Waiting Safe for Some at Risk of Glaucoma 2Health News:Stroke Risk Runs in the Family 2Health News:Stroke Risk Runs in the Family 3Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 2Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 3Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 4Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 5Health News:Chicago AIDS Advocates Launch Female Condom Campaign 2Health News:Chicago AIDS Advocates Launch Female Condom Campaign 3Health News:Chicago AIDS Advocates Launch Female Condom Campaign 4Health News:Chicago AIDS Advocates Launch Female Condom Campaign 5Health News:Chicago AIDS Advocates Launch Female Condom Campaign 6Health News:Chicago AIDS Advocates Launch Female Condom Campaign 7Health News:Chicago AIDS Advocates Launch Female Condom Campaign 8Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 2Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 3Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 4Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 5Health News:Highmark and its Employees Donate $161,686 for Haiti Disaster Relief Efforts 2Health News:Highmark and its Employees Donate $161,686 for Haiti Disaster Relief Efforts 3
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The Precedent establishes a new generation of revision hip stems....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Calcar replacement stems provide options for revision and trochanteric fractures. Revision hip surgery and trauma often require prosthetic designs that replace proximal medial calcar bone loss....
Medicine Products: